Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up

[1]  D. Grignon,et al.  Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Parmar,et al.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.

[3]  R. Eeles,et al.  Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects , 2005, British Journal of Cancer.

[4]  M. Sydes,et al.  Escalated-dose Conformai Radiotherapy for Localised Prostate Cancer: Long-term Overall Survival Results From the MRC RT01 Randomised Controlled Trial , 2011 .

[5]  D. Kuban,et al.  Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? , 2008, International journal of radiation oncology, biology, physics.

[6]  Christopher U. Jones,et al.  Radiotherapy and short-term androgen deprivation for localized prostate cancer. , 2011, The New England journal of medicine.

[7]  J. Lebesque,et al.  Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[8]  Kyounghwa Bae,et al.  Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Voelker.  No Survival Advantage , 1998 .

[10]  D. Dearnaley,et al.  Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  T. Peters,et al.  Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. , 2009, Journal of clinical epidemiology.

[12]  C. D’Este,et al.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. , 2011, The Lancet. Oncology.

[13]  Clinical and technical aspects of conformal therapy , 1993 .

[14]  M. Roach,et al.  Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[15]  J. Manola,et al.  6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. , 2004, JAMA.

[16]  A. Fortin,et al.  The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. , 2004, The Journal of urology.

[17]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. , 2012, The Lancet. Oncology.

[18]  B Pickett,et al.  Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy. , 1994, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[19]  T. Wilt,et al.  Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. , 2009, Cancer treatment reviews.

[20]  M. Milella,et al.  Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? , 2009, Cancer.

[21]  D. Grignon,et al.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. , 2001, International journal of radiation oncology, biology, physics.

[22]  M. Parmar,et al.  Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08) , 2011 .

[23]  G. Viani,et al.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. , 2009, International journal of radiation oncology, biology, physics.

[24]  D P Dearnaley,et al.  Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  S. Webb,et al.  An evaluation of three-field coplanar plans for conformal radiotherapy of prostate cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  D. Dearnaley,et al.  Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. , 1992, British journal of urology.

[27]  D. Kuban,et al.  Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? , 2012, European journal of cancer.

[28]  F. Hamdy,et al.  Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. , 2010, European journal of cancer.

[29]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[30]  D. Kuban,et al.  Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.